185 related articles for article (PubMed ID: 31164331)
21. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.
Liu HL; Hoppe RT; Kohler S; Harvell JD; Reddy S; Kim YH
J Am Acad Dermatol; 2003 Dec; 49(6):1049-58. PubMed ID: 14639383
[TBL] [Abstract][Full Text] [Related]
22. CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group.
Paulli M; Berti E; Rosso R; Boveri E; Kindl S; Klersy C; Lazzarino M; Borroni G; Menestrina F; Santucci M
J Clin Oncol; 1995 Jun; 13(6):1343-54. PubMed ID: 7751878
[TBL] [Abstract][Full Text] [Related]
23. Risk of systemic lymphoma in patients with cutaneous CD30+ lymphoproliferative disorders: A single center retrospective cohort analysis.
Chen J; Martinez A; Shinohara MM
J Am Acad Dermatol; 2024 Jul; 91(1):134-135. PubMed ID: 38490370
[No Abstract] [Full Text] [Related]
24. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders.
Kempf W; Levi E; Kamarashev J; Kutzner H; Pfeifer W; Petrogiannis-Haliotis T; Burg G; Kadin ME
J Cutan Pathol; 2002 May; 29(5):295-300. PubMed ID: 12100631
[TBL] [Abstract][Full Text] [Related]
25. CD30+ neoplasms of the skin.
Duvic M
Curr Hematol Malig Rep; 2011 Dec; 6(4):245-50. PubMed ID: 21850406
[TBL] [Abstract][Full Text] [Related]
26. Primary cutaneous CD30+ lymphoproliferative disorder--a 10-year follow-up. A case report and differential diagnosis.
Szpor J; Dyduch G; Gałazka K; Bahyrycz J; Stój A; Tomaszewska R
Pol J Pathol; 2009; 60(1):43-8. PubMed ID: 19670703
[TBL] [Abstract][Full Text] [Related]
27. Primary cutaneous anaplastic large cell lymphoma.
Brown RA; Fernandez-Pol S; Kim J
J Cutan Pathol; 2017 Jun; 44(6):570-577. PubMed ID: 28342276
[TBL] [Abstract][Full Text] [Related]
28. Perils and pitfalls regarding differential diagnosis and treatment of primary cutaneous anaplastic large-cell lymphoma.
Diamantidis MD; Myrou AD
ScientificWorldJournal; 2011 May; 11():1048-55. PubMed ID: 21552770
[TBL] [Abstract][Full Text] [Related]
29. Polymorphism of the CD30 promoter microsatellite repressive element is associated with development of primary cutaneous lymphoproliferative disorders.
Franchina M; Kadin ME; Abraham LJ
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1322-5. PubMed ID: 15894695
[TBL] [Abstract][Full Text] [Related]
30. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
Kempf W
Semin Diagn Pathol; 2017 Jan; 34(1):22-35. PubMed ID: 27993440
[TBL] [Abstract][Full Text] [Related]
31. Expression of CD44 and CD44v6 in primary cutaneous CD30 positive T-cell lymphoproliferative disorders.
Liang X; Smoller BR; Golitz LE
J Cutan Pathol; 2002 Sep; 29(8):459-64. PubMed ID: 12207739
[TBL] [Abstract][Full Text] [Related]
32. Mucosal CD30-positive T-cell lymphoproliferations of the head and neck show a clinicopathologic spectrum similar to cutaneous CD30-positive T-cell lymphoproliferative disorders.
Sciallis AP; Law ME; Inwards DJ; McClure RF; Macon WR; Kurtin PJ; Dogan A; Feldman AL
Mod Pathol; 2012 Jul; 25(7):983-92. PubMed ID: 22388754
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the t(2;5) (p23;q35) translocation in CD30+ primary cutaneous lymphoproliferative disorders and Hodgkin's disease.
Wood GS
Leuk Lymphoma; 1998 Mar; 29(1-2):93-101. PubMed ID: 9638979
[TBL] [Abstract][Full Text] [Related]
34. Th2 cytokine mRNA expression in primary cutaneous CD30-positive lymphoproliferative disorders: successful treatment with recombinant interferon-gamma.
Yagi H; Tokura Y; Furukawa F; Takigawa M
J Invest Dermatol; 1996 Dec; 107(6):827-32. PubMed ID: 8941669
[TBL] [Abstract][Full Text] [Related]
35. Primary cutaneous CD30+ lymphoproliferative disorders: new insights into biology and therapy.
Querfeld C; Kuzel TM; Guitart J; Rosen ST
Oncology (Williston Park); 2007 May; 21(6):689-96; discussion 699-700,. PubMed ID: 17564326
[TBL] [Abstract][Full Text] [Related]
36. Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination.
Brumfiel CM; Patel MH; DiCaudo DJ; Rosenthal AC; Pittelkow MR; Mangold AR
Leuk Lymphoma; 2021 Oct; 62(10):2554-2555. PubMed ID: 33974494
[No Abstract] [Full Text] [Related]
37. Of lymphocytes and cutaneous epithelium: keratoacanthomatous hyperplasia in CD30+ lymphoproliferative disorders and CD30+ cells associated with keratoacanthoma.
Resnik KS; Kutzner H
Am J Dermatopathol; 2010 May; 32(3):314-315. PubMed ID: 19915450
[No Abstract] [Full Text] [Related]
38. Practical Management of CD30⁺ Lymphoproliferative Disorders.
Hughey LC
Dermatol Clin; 2015 Oct; 33(4):819-33. PubMed ID: 26433852
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous CD30 lymphoproliferative disorders and similar conditions: a clinical and pathologic prospective on a complex issue.
Guitart J; Querfeld C
Semin Diagn Pathol; 2009 Aug; 26(3):131-40. PubMed ID: 20043512
[TBL] [Abstract][Full Text] [Related]
40. Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity.
Schwartz Z; Bowe RB; Coleman M; Magro CM
Ann Diagn Pathol; 2018 Dec; 37():57-61. PubMed ID: 30292067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
